Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of Semaglutide on Bone Health
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice. Given that weight loss is associated with bone loss, its effect on bone health has recently raised concerns. Therefore, the goal of this clinical trial is to learn the effect of semaglutide on bone mineral density and fractures in patients with type 2 diabetes. The investigators will compare semaglutide combined with metformin to metformin alone to see if semaglutide treatment has effects on bone mineral density and bone turnover markers in patients with type 2 diabetes after 12 months. The intervention group will receive semaglutide combined with metformin for 12 months, while the control group will receive metformin alone for the same duration. After 12 months of treatment, the investigators will compare the bone mineral density, fracture incidence, and levels of bone turnover markers between the two groups.
Official title: The Effect of Semaglutide on Osteoporotic Fractures in Patients With Type 2 Diabetes
Key Details
Gender
All
Age Range
50 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-09-15
Completion Date
2026-12-31
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
semaglutide combined with metformin
The initial dose of semaglutide is 0.25 mg once weekly. After 4 weeks, the dose is adjusted to 0.5 mg once weekly. After another 4 weeks, the dose is adjusted to 1 mg once weekly. During the same period, they will take metformin (500mg each time, three times a day) for treatment. The treatment course is 12 months.
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China